Neurothera Labs Inc., a clinical-stage biotech company and majority-owned subsidiary of SciSparc Ltd., has entered into a non-binding term sheet to acquire a 55% equity interest in a pioneering quantum computing bio data analysis company. The transaction, if completed, will see Neurothera issue common shares equal to 40% of its post-transaction, non-diluted share capital to certain selling shareholders of the target company. The quantum-enabled clinical analytics firm specializes in leveraging quantum computing to enhance the storage, manipulation, and analysis of bio data, with the goal of accelerating medical research and redefining clinical trials through advanced machine learning and data science. Completion of the acquisition remains subject to due diligence, negotiation of definitive agreements, and customary closing conditions.